David H. Bergstrom

Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury

Antares Pharma, Inc. is a specialty pharmaceutical company, which engages in the development and commercialization of pharmaceutical products and technologies in targeted therapeutic areas. Its products include XYOSTED injection, OTREXUP injection for subcutaneous use, and Sumatriptan injection. The company was founded in February 1979 and is headquartered in Ewing, NJ.

NovaDel Pharma, Inc. engages in developing oral spray formulations for different types of drugs. It develops oral spray and pharmaceutical products for angina pectoris, insomia, migraine headaches, and disorders of the central nervous system. The company was founded in 1982 and is headquartered in Bridgewater, NJ.

Eurofins Advantar Laboratories, Inc. specializes in analytical development and formulation services for large molecule and small molecule programs, medical devices, and novel combination products. Its services include biophysical characterization, bimolecular and small molecules, FTE programs, data review support, regulatory and CMC consulting, litigation support and expert testimony, PAI audit and FDA response support. The company was founded by David F. Hale, John Alaimo, Richard A. Kenley, and Edward Foster in 2008 and is headquartered in San Diego, CA.

Bridge Therapeutics, Inc. is a pharmaceutical company. The firm specializes in chronic pain and opioid addiction. The company was founded by Greg Sullivan and is headquartered in Birmingham, AL.